XML 94 R84.htm IDEA: XBRL DOCUMENT v3.23.1
TAXES (Details Narrative) - USD ($)
 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Mar. 31, 2023
Mar. 31, 2022
Jun. 30, 2019
Jun. 30, 2018
Income Tax Disclosure [Abstract]              
Federal statutory income tax rate, percent       25.00%   21.00% 28.00%
Reduced income tax, description       Biowin is subject to corporate income tax at a reduced rate of 15% starting from December 2019, when it was approved by local government as a High and New Technology Enterprises (“HNTEs”), to December 2022. In December 2022, the Company successfully renewed its HNTE certification with local government and will continue to enjoy the reduced income tax rate of 15% for another three years through December 2025.      
Income tax expenses $ (33,089) $ (29)   $ (33,089) $ (6,507)   $ 744,766
Income taxes percentage, description       The Company elects to pay the transition tax over an eight-year period using specified percentages (eight percent per year for the first five years, 15 percent in year six, 20 percent in year seven, and 25 percent in year eight).      
Value added tax rate, description       All of the Company’s products that were sold in the PRC were subject to a Chinese value-added tax at rates ranging from 3% to 13%, depending on the type of products sold. For overseas sales, VAT is exempted on the exported goods. The amount of VAT liability is determined by applying the applicable tax rate to the invoiced amount of goods sold (output VAT) less VAT paid on purchases made with the relevant supporting invoices (input VAT). Under commercial practice in the PRC, the Company pays VAT based on tax invoices issued. The tax invoices may be issued subsequent to the date on which revenue is recognized, and there may be a considerable delay between the date on which the revenue is recognized and the date on which the tax invoice is issued      
Tax penalties $ 0 $ 0 $ 0 $ 0